Neuromuscular Adverse Events Associated with Anti-PD-1 Monoclonal Antibodies
Neurol 92:663-674, Johansen, A.,et al, 2019
GQ1b-Seronegative Miller Fisher Syndrome Associated with Pembrolizumab
J Neuro-Ophthal 39:394-396, Green, K.E.,et al, 2019
Antibody-Mediated Encephalitis
NEJM 378:840-851, Dalmau, J.,et al, 2018
Acute demyelinating polyneuropathy induced by nivolumab
JNNP 89:435-437, Fukumoto, Y.,et al, 2018
Pembrolizumab-Induced Myasthenia Gravis
Neurol 91:e1365-e1367, Algaeed, M.,et al, 2018
Autoimmune Encephalitides: A Broadening Field of Treatable Conditions
Neurologist 22:1-13, Kalman, B., 2017
Myasthenia Gravis
NEJM 375:2570-2581, Gilhus, N.E.,et al, 2016
Acute Demyelinating Polyneuropathy Caused by Nivolumab in a Man with Metastatic Non-Small Cell Lung Cancer
J Gerontol Geriatr Res 5:3, Sabeeh-Ur-Rehman, B. & Bhaumik, S., 2016
Neurological Immune-Related Adverse Events of Ipilimumab
Pract Neurol 13:278-280, Bot, I.,et al, 2013
Late onset autism and anti-NMDA-receptor encephalitis
Lancet 378:98;378, Creten, C.,et al, 2011
Monoclonal Antibody Therapies and Neurologic Disorders
Arch Neurol 65:1162-1165, Novack,J.C.,et al., 2008
Treatment of Guillain-Barre Syndrome with Anti-T Cell Monoclonal Antibodies
JNNP 54:51-54, Feasby,T.E., 1991
OKT3 Encephalopathy
Ann Neurol 28:837-838, Coleman,A.E.&Norman,D.J., 1990